CRSP Stock Analysis: Crispr Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.360m USD | 12M Return: -28.7% | CH0334081137 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 92.6M
Qual. Beats: 0
Rev. Trend: -89.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 9.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CRISPR Therapeutics AG (NASDAQ: CRSP) is a Swiss-based biotechnology company developing gene-editing medicines using its proprietary CRISPR/Cas9 platform, which enables precise modification of genomic DNA sequences. The company was founded in 2013 and listed on the U.S. market in October 2016, and its mid-cap market value reflects its position as a clinical-stage player in the gene-editing space. It has a broad pipeline spanning hemoglobinopathies, CAR T cell therapies, in vivo gene editing, and type 1 diabetes, with its lead product, CASGEVY, being an ex vivo gene-edited cell therapy approved for transfusion-dependent beta-thalassemia and severe sickle cell disease. Strategic collaboration with Vertex Pharmaceuticals supports CASGEVYs commercialization and broader development efforts, illustrating the partnership-driven model common in biotech where large pharma helps fund and distribute advanced therapies.
- CASGEVY launch uptake drives sickle cell and beta-thalassemia revenue ramp
- Vertex partnership milestone payments expand operating runway
- In vivo gene editing pipeline readouts validate platform expansion potential
| Net Income: -451.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 4.25 > 1.0 |
| NWC/Revenue: 16.7k% < 20% (prev 4.36k%; Δ 12.4k% < -1%) |
| CFO/TA -0.14 > 3% & CFO -369.6m > Net Income -451.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (96.5m) vs 12m ago 10.85% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.57% > 50% (prev 1.84%; Δ -1.27% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.84 (Total Current Assets 2.37b - Total Current Liabilities 132.9m) / Total Assets 2.65b |
| B: -0.82 (Retained Earnings -2.16b / Total Assets 2.65b) |
| C: -0.20 (EBIT TTM -472.7m / Avg Total Assets 2.34b) |
| D: 1.93 (Book Value of Equity 1.75b / Total Liabilities 904.2m) |
| Altman-Z'' = 3.55 = A |
As of October 11, 2026, the stock is trading at USD 53.39 with a total of 1,465,256 shares traded. Over the past week, the price has changed by -3.68%, over one month by -0.11%, over three months by -5.24% and over the past year by -28.74%.
Current recommended Stop Loss: 47.30 (which is 11.4% or 2 ATR below the current price).
Crispr Therapeutics has received a consensus analysts rating of 3.95. Therefore, it is recommended to buy CRSP.
- StrongBuy: 8
- Buy: 5
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 87.6 | 64% |
P/E Forward = 23.3645
P/S = 400.2146
P/B = 3.087
P/EG = -0.2142
Revenue TTM = 13.4m USD
EBIT TTM = -472.7m USD
EBITDA TTM = -454.0m USD
Long Term Debt = 586.2m USD (from longTermDebt, last quarter)
Short Term Debt = 18.6m USD (from shortTermDebt, last quarter)
Debt = 981.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 197.6m
Net Debt = -1.38b USD (calculated: Debt 981.3m - CCE 2.36b)
Enterprise Value = 3.98b USD (5.36b + Debt 981.3m - CCE 2.36b)
Interest Coverage Ratio = unknown (Ebit TTM -472.7m / Interest Expense TTM 0.0)
EV/FCF = -10.80x (Enterprise Value 3.98b / FCF TTM -368.3m)
FCF Yield = -9.26% (FCF TTM -368.3m / Enterprise Value 3.98b)
FCF Margin = -2.75k% (FCF TTM -368.3m / Revenue TTM 13.4m)
Net Margin = -3.37k% (Net Income TTM -451.1m / Revenue TTM 13.4m)
Gross Margin = unknown ((Revenue TTM 13.4m - Cost of Revenue TTM 218.9m) / Revenue TTM)
Tobins Q-Ratio = 1.50 (Enterprise Value 3.98b / Total Assets 2.65b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 981.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -373.4m (EBIT -472.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.45 (Total Current Assets 2.37b / Total Current Liabilities 144.2m)
Debt / Equity = 0.56 (Debt 981.3m / totalStockholderEquity, last quarter 1.75b)
Debt / EBITDA = 3.05 (negative EBITDA) (Net Debt -1.38b / EBITDA -454.0m)
Debt / FCF = 3.75 (negative FCF - burning cash) (Net Debt -1.38b / FCF TTM -368.3m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.28% (Net Income -451.1m / Total Assets 2.65b)
RoE = -24.39% (Net Income TTM -451.1m / Total Stockholder Equity 1.85b)
RoCE = -19.41% (EBIT -472.7m / Capital Employed (Equity 1.85b + L.T.Debt 586.2m))
RoIC = -14.73% (negative operating profit) (NOPAT -373.4m / Invested Capital 2.54b)
WACC = 10.09% (E(5.36b)/V(6.34b) * Re(11.94%) + D(981.3m)/V(6.34b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.28 | Cagr: 7.63%
[DCF] Fair Price = unknown (Cash Flow -368.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.48 | # QB: 0
Revenue Correlation: -89.33 | Revenue CAGR: -79.21% | SUE: 0.29 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.05 | Chg30d=+10.60% | Revisions=+50% | Analysts=17
EPS current Year (2026-12-31): EPS=-4.45 | Chg30d=+0.00% | Revisions=+50% | GrowthEPS=+31.3% | GrowthRev=+1063.3%
EPS next Year (2027-12-31): EPS=-3.50 | Chg30d=+0.00% | Revisions=+82% | GrowthEPS=+21.3% | GrowthRev=+283.5%
[Analyst] Revisions Ratio: +70% (up=35, down=5)